HK1209111A1 - 醌系化合物及其用於癌症治療的用途 - Google Patents

醌系化合物及其用於癌症治療的用途

Info

Publication number
HK1209111A1
HK1209111A1 HK15109758.6A HK15109758A HK1209111A1 HK 1209111 A1 HK1209111 A1 HK 1209111A1 HK 15109758 A HK15109758 A HK 15109758A HK 1209111 A1 HK1209111 A1 HK 1209111A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
quinone compounds
quinone
compounds
Prior art date
Application number
HK15109758.6A
Other languages
English (en)
Inventor
Alan Mcgown
John Hadfield
John Butler
Original Assignee
Onco Nx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco Nx Ltd filed Critical Onco Nx Ltd
Publication of HK1209111A1 publication Critical patent/HK1209111A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D203/00Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK15109758.6A 2012-07-30 2015-10-06 醌系化合物及其用於癌症治療的用途 HK1209111A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1213486.2A GB201213486D0 (en) 2012-07-30 2012-07-30 Quinone compounds and their uses for the treatment of cancer
PCT/EP2013/065968 WO2014020012A1 (en) 2012-07-30 2013-07-30 Quinone compounds and their uses for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1209111A1 true HK1209111A1 (zh) 2016-03-24

Family

ID=46881339

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109758.6A HK1209111A1 (zh) 2012-07-30 2015-10-06 醌系化合物及其用於癌症治療的用途

Country Status (17)

Country Link
US (1) US9266829B2 (zh)
EP (1) EP2882743B1 (zh)
JP (1) JP6317742B2 (zh)
KR (1) KR102142164B1 (zh)
CN (1) CN104583200B (zh)
AU (1) AU2013298653B2 (zh)
BR (1) BR112015001837B1 (zh)
CA (1) CA2880021C (zh)
DK (1) DK2882743T3 (zh)
ES (1) ES2662917T3 (zh)
GB (2) GB201213486D0 (zh)
HK (1) HK1209111A1 (zh)
IN (1) IN2015DN01223A (zh)
MX (1) MX361650B (zh)
NO (1) NO2882743T3 (zh)
RU (1) RU2688675C2 (zh)
WO (1) WO2014020012A1 (zh)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156744A (en) * 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
KR20070032795A (ko) * 2004-06-21 2007-03-22 허치슨 메디파르마 엔터프라이즈 리미티드 항암 화학요법
EP2134322B1 (en) * 2007-03-13 2019-02-20 Spectrum Pharmaceuticals, Inc. Intravesical apaziquone administration following transurethral resection for treating bladder cancer

Also Published As

Publication number Publication date
CN104583200A (zh) 2015-04-29
GB2519004A (en) 2015-04-08
WO2014020012A1 (en) 2014-02-06
JP2015524815A (ja) 2015-08-27
AU2013298653A1 (en) 2015-02-19
ES2662917T3 (es) 2018-04-10
MX361650B (es) 2018-12-13
KR20150036215A (ko) 2015-04-07
EP2882743B1 (en) 2017-12-13
AU2013298653B2 (en) 2017-10-19
CA2880021C (en) 2020-01-14
IN2015DN01223A (zh) 2015-06-26
JP6317742B2 (ja) 2018-04-25
GB2519004B (en) 2016-03-30
DK2882743T3 (en) 2018-03-12
US20150210639A1 (en) 2015-07-30
BR112015001837B1 (pt) 2021-11-16
US9266829B2 (en) 2016-02-23
RU2688675C2 (ru) 2019-05-22
CA2880021A1 (en) 2014-02-06
NO2882743T3 (zh) 2018-05-12
KR102142164B1 (ko) 2020-08-06
CN104583200B (zh) 2017-07-25
BR112015001837A2 (pt) 2017-07-04
EP2882743A1 (en) 2015-06-17
GB201213486D0 (en) 2012-09-12
RU2015105036A (ru) 2016-09-20
MX2015000969A (es) 2015-09-23

Similar Documents

Publication Publication Date Title
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
IL261659A (en) Brain cancer treatment
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP2920308A4 (en) TREATMENT OF CANCER
IL263781A (en) Combined treatment of ovarian cancer
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
HK1214128A1 (zh) 癌症的治療
HK1205254A1 (zh) 治療癌症的方法
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (zh) 癌症治療
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
DK2872176T3 (en) Cancer treatment
IL236321A0 (en) Combined treatment for cancer and immunosuppression
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201217890D0 (en) Treatment of cancer
HK1209111A1 (zh) 醌系化合物及其用於癌症治療的用途
HK1200094A1 (zh) 免疫調節劑用於治療癌症的用途
IL233495A0 (en) Combination for cancer treatment
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer
GB201208296D0 (en) Treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200730